Clinical TrialApr 14, 2026, 07:05 PM
Telix Doses First Patient in Pivotal Phase 3 Glioblastoma Trial
AI Summary
Telix Pharmaceuticals announced the dosing of the first patient with TLX101-Tx in its pivotal Phase 3 IPAX BrIGHT trial for recurrent glioblastoma. This milestone marks the first radiopharmaceutical therapy to enter Phase 3 development for this aggressive brain cancer, an area with significant unmet medical need and limited treatment options. The global study will assess the safety and efficacy of TLX101-Tx in combination with chemotherapy, building on promising data from earlier trials.
Key Highlights
- First patient dosed in pivotal Phase 3 IPAX BrIGHT trial for recurrent glioblastoma.
- TLX101-Tx is the first radiopharmaceutical therapy to enter Phase 3 for glioblastoma.
- Previous trials showed median overall survival of 13 months (IPAX-1) and 12.4 months (IPAX-Linz).
- Only two drugs approved by the FDA for glioblastoma in the past 25 years.
- Early access program in Europe has dosed 18 patients with TLX101-Tx.